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A B S T R A C T
Background
Severe pre-eclampsia can cause significant mortality and morbidity for both mother and child, particularly when it occurs remote from
term, between 24 and 34 weeks' gestation. The only known cure for this disease is delivery. Some obstetricians advocate early delivery to
ensure that the development of serious maternal complications, such as eclampsia (fits) and kidney failure are prevented. Others prefer
a more expectant approach, delaying delivery in an attempt to reduce the mortality and morbidity for the child that is associated with
being born too early.
Objectives
To evaluate the comparative benefits and risks of a policy of early delivery by induction of labour or by caesarean section, aJer suKicient
time has elapsed to administer corticosteroids, and allow them to take eKect; with a policy of delaying delivery (expectant care) for women
with severe pre-eclampsia between 24 and 34 weeks' gestation.
Search methods
For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials
Registry Platform (ICTRP) on 27 November 2017, and reference lists of retrieved studies.
Selection criteria
Randomised trials comparing the two intervention strategies for women with early onset, severe pre-eclampsia. Trials reported in an
abstract were eligible for inclusion, as were cluster-trial designs. We excluded quasi-randomised trials.
Data collection and analysis
Three review authors independently assessed trials for inclusion and risk of bias, extracted data, and checked them for accuracy. We
assessed the quality of the evidence for specified outcomes using the GRADE approach.
Main results
We included six trials, with a total of 748 women in this review. All trials included women in whom there was no overriding indication
for immediate delivery in the fetal or maternal interest. Half of the trials were at low risk of bias for methods of randomisation and
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allocation concealment; and four trials were at low risk for selective reporting. For most other domains, risk of bias was unclear. There were
insuKicient data for reliable conclusions about the comparative eKects on most outcomes for the mother. Two studies reported on maternal
deaths; neither study reported any deaths (two studies; 320 women; low-quality evidence). It was uncertain whether interventionist care
reduced eclampsia (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.06 to 15.58; two studies; 359 women) or pulmonary oedema (RR
0.45, 95% CI 0.07 to 3.00; two studies; 415 women), because the quality of the evidence for these outcomes was very low. Evidence
from two studies suggested little or no clear diKerence between the interventionist and expectant care groups for HELLP (haemolysis,
elevated liver enzymes, and low platelets) syndrome (RR 1.09, 95% CI 0.62 to 1.91; two studies; 359 women; low-quality evidence). No study
reported on stroke. With the addition of data from two studies for this update, there was now evidence to suggest that interventionist care
probably made little or no diKerence to the incidence of caesarean section (average RR 1.01, 95% CI 0.91 to 1.12; six studies; 745 women;
Heterogeneity: Tau2 = 0.01; I2 = 63%).
For the baby, there was insuKicient evidence to draw reliable conclusions about the eKects on perinatal deaths (RR 1.11, 95% CI 0.62 to
1.99; three studies; 343 women; low-quality evidence). Babies whose mothers had been allocated to the interventionist group had more
intraventricular haemorrhage (RR 1.94, 95% CI 1.15 to 3.29; two studies; 537 women; moderate-quality evidence), more respiratory distress
caused by hyaline membrane disease (RR 2.30, 95% CI 1.39 to 3.81; two studies; 133 women), required more ventilation (RR 1.50, 95% CI
1.11 to 2.02; two studies; 300 women), and were more likely to have a lower gestation at birth (mean diKerence (MD) -9.91 days, 95% CI
-16.37 to -3.45 days; four studies; 425 women; Heterogeneity: Tau2 = 31.74; I2 = 76%). However, babies whose mothers had been allocated
to the interventionist group were no more likely to be admitted to neonatal intensive care (average RR 1.19, 95% CI 0.89 to 1.60; three
studies; 400 infants; Heterogeneity: Tau2 = 0.05; I2 = 84%). Babies born to mothers in the interventionist groups were more likely to have
a longer stay in the neonatal intensive care unit (MD 7.38 days, 95% CI -0.45 to 15.20 days; three studies; 400 women; Heterogeneity: Tau2
= 40.93, I2 = 85%) and were less likely to be small-for-gestational age (RR 0.38, 95% CI 0.24 to 0.61; three studies; 400 women). There were
no clear diKerences between the two strategies for any other outcomes.
Authors' conclusions
This review suggested that an expectant approach to the management of women with severe early onset pre-eclampsia may be associated
with decreased morbidity for the baby. However, this evidence was based on data from only six trials. Further large, high-quality trials are
needed to confirm or refute these findings, and establish if this approach is safe for the mother.
P L A I N   L A N G U A G E   S U M M A R Y
Interventionist versus expectant care for severe pre-eclampsia before term
What is the issue?
Women who develop pre-eclampsia (high blood pressure and protein in the urine) before 34 weeks of pregnancy (early onset) are at risk of
severe complications, and even death. These involve the woman's liver, kidneys, and clotting system, and cause neurological disturbances,
such as headache, visual disturbances, and fits. If the placenta is involved, this can cause growth restriction or reduced amniotic fluid,
placing the baby at risk.
Why is this important?
The only known cure for pre-eclampsia is delivery of the baby. Being born too early can in itself have problems for the baby, even with
the administration of corticosteroids 24 to 48 hours beforehand, to help mature the lungs. Some hospitals follow a policy of early delivery,
within 24 to 48 hours, called interventionist management, whilst others prefer to delay delivery until it is no longer possible to safely
stabilise the woman's condition, called expectant management.
What evidence did we find?
We searched for evidence in November 2017 and identified six randomised trials. This review included six trials that randomly assigned
women to a policy of interventionist management or expectant management when presenting with severe pre-eclampsia before 34 weeks
of pregnancy. A total of 748 women were included in these six trials. Babies born to women allocated to an interventionist approach were
probably more likely to experience adverse eKects such as bleeding in the brain (intraventricular haemorrhage). They may also have been
more likely to require ventilation, have a longer stay in the neonatal unit, have a lower gestation at birth in days, and weigh less at birth than
those babies born to women allocated to an expectant management approach. There was insuKicient evidence for reliable conclusions
about the eKects on perinatal deaths. Babies whose mothers had been allocated to the interventionist group were no more likely to be
admitted to neonatal intensive care.
There were no maternal deaths in the two studies that reported this outcome. The evidence was very low-quality for the outcome of fits
or convulsions (eclampsia), or of fluid in the lungs (pulmonary oedema), and so it was uncertain whether interventionist care made any
clear diKerence to the mothers' health. Evidence from two studies suggested little or no clear diKerence between the interventionist and
expectant care groups for a severe form of pre-eclampsia, which aKects the liver and blood clotting, called HELLP syndrome, which stands
for haemolysis (breakdown of red blood cells), elevated liver enzymes (a sign of liver damage), and low platelets (platelets help the blood
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to clot). None of the studies reported on the incidence of stroke in the mother. With the addition of data from two studies for this update,
there was now evidence to suggest that interventionist care probably made little or no diKerence to the caesarean section rate.
What does this mean?
In the absence of an over-riding maternal or fetal indication for immediate delivery, delay may be more beneficial for the baby. However,
there were insuKicient data to enable us to draw reliable conclusions about the comparative eKects on most outcomes for the mother, and
hence the maternal safety of an expectant approach.
This evidence was based on data from only six trials. Further large trials with long-term follow-up of the children are needed to confirm or
refute whether expectant care is better than early delivery for women who suKer from severe pre-eclampsia before 34 weeks of pregnancy.
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Summary of findings for the main comparison.   Interventionist care compared to expectant (delayed delivery) care for severe pre-eclampsia for
severe pre-eclampsia between 24 and 34 weeks' gestation
Interventionist care compared to expectant (delayed delivery) care for severe pre-eclampsia
Patient or population: women with severe pre-eclampsia between 24 and 34 weeks' gestation
Setting: hospital settings 
Intervention: interventionist care
Comparison: expectant (delayed delivery) care
Anticipated absolute effects* (95% CI)Outcomes
Risk with expectant (de-
layed delivery) care
Risk with Interventionist
care
Relative effect
(95% CI)
№ of partici-
pants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Study populationMaternal death
0 per 1000 0 per 1000
(0 to 0)
not estimable 320
(2 RCTs)
⊕⊕⊝⊝
LOW a,b
There were no
deaths in ei-
ther group
Study populationEclampsia
6 per 1000 5 per 1000
(0 to 87)
RR 0.98
(0.06 to 15.58)
359
(2 RCTs)
⊕⊝⊝⊝
VERY LOW c,d
 
Stroke (brain damage) - - - - - outcome not
reported
Study populationHELLP syndrome
111 per 1000 121 per 1000
(69 to 212)
RR 1.09
(0.62 to 1.91)
359
(2 RCTs)
⊕⊕⊝⊝
LOW c,e
 
Study populationPulmonary oedema
10 per 1000 4 per 1000
(1 to 29)
RR 0.45
(0.07 to 3.00)
415
(3 RCTs)
⊕⊝⊝⊝
VERY LOW c,f
 
Study populationPerinatal mortality or peri-
natal death
105 per 1000 117 per 1000
RR 1.11
(0.62 to 1.99)
343
(3 RCTs)
⊕⊕⊝⊝
LOW e,g
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(65 to 209)
Study populationIntraventricular haemor-
rhage or hypoxic ischaemic
encephalopathy 66 per 1000 127 per 1000
(75 to 216)
RR 1.94
(1.15 to 3.29)
537
(2 RCTs)
⊕⊕⊕⊝
MODERATE c
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
 
CI: Confidence interval; RR: Risk ratio; HELLP syndrome: haemolysis, elevated liver enzymes, and low platelets.
Hospital settings were in USA, South Africa, Egypt, The Netherlands, Latin America (Panama, Pennsylvania, Mexico, Venezuela, Guatemala, Peru, Ecuador), and Europe
(Belgium, Cyprus, Czech Republic, Germany, Hungary, Greece, Italy, Netherlands, Poland, Portugal, Saudi Arabia, Slovenia, UK).
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
a Limitations in study design (no blinding; -1)
b No events (-1)
c Limitations in study design (no blinding) for one of the studies (-1)
d Low event rate, small sample size and wide CI crossing the line of no eKect (-2)
e Wide CI crossing the line of no eKect (-1)
f Small number of events and wide CI crossing the line of no eKect (-2)
g Limitations in study design (-1)
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B A C K G R O U N D
Pre-eclampsia is a multisystem disorder that is usually associated
with raised blood pressure and proteinuria, but can also involve the
woman's liver, kidneys, clotting system, or brain. If the placenta is
involved, this may lead to growth restriction or premature birth.
Pre-eclampsia is a relatively common complication of pregnancy,
and can occur at any time during the second half of pregnancy, or
in the first few weeks aJer delivery. Prediction models for adverse
maternal outcome have been developed and validated in recent
times, but there is still a paucity of data to guide the clinician on the
timing of delivery to ensure safety of both the mother and the baby
in the long term (von Dadelszen 2011). Pre-eclampsia is described
in more detail in the generic protocol on interventions for treatment
of pre-eclampsia and its consequences (Duley 2009).
Description of the condition
Hypertension in pregnancy is defined as a systolic blood pressure
of 140 mmHg or more, a diastolic pressure of 90 mmHg or more,
or both. To be diagnosed with pre-eclampsia, the hypertension
has to rise de novo aJer 20 weeks of pregnancy, combined with
proteinuria, defined as more than 300 mg of total protein in a 24-
hour urine collection (Davey 1988). Proteinuria can also be assessed
using a spot urine test, which measures the protein to creatinine
ratio. A protein:creatinine ratio of 30 mg/mmol correlates with a
24-hour protein excretion of more than 300 mg in 24 hours (Morris
2012). This method of estimating the amount of protein being
excreted has several advantages over the 24-hour urine collection,
and was endorsed by NICE (NICE 2010). However, pre-eclampsia
is a multi-system disorder, and the diagnosis of hypertension and
proteinuria is considered to be too restrictive for clinical practice.
Clinicians are all too aware that the disease can present in several
ways, and it is necessary to be vigilant when assessing women with
symptoms and signs that are strongly associated with the disease.
This has led to a widening of the definition for clinical purposes,
to include the following: de novo hypertension aJer 20 weeks'
gestation, and new onset of one of the following: a) proteinuria, as
defined above; b) renal insuKiciency (creatinine > 0.09 mmol/L, or
oliguria; c) liver disease (raised transaminases, severe right upper
quadrant or epigastric pain, or a combination); d) neurological
problems: convulsions (eclampsia), hyper-reflexia with clonus
(involuntary muscular contractions), severe headaches, persistent
visual disturbances (scotoma); e) haematological disturbances:
thrombocytopenia (reduced numbers of platelets), disseminated
intravascular coagulation, haemolysis; or f) fetal growth restriction
(Brown 2001).
There is no widely accepted definition of severe pre-eclampsia
(Duley 2009). Nevertheless, the features described above, in
combination with the early onset of the disease between 24
and 34 weeks' gestation, would be considered by most clinicians
to represent severe pre-eclampsia. Therefore, we did not define
further or categorise 'severity'.
Description of the intervention
In clinical practice, some units advocate early delivery, which
has been referred to as 'aggressive management' (Sibai 1984).
In this review, we prefer the term 'interventionist'. This means
delivery by either induction of labour or caesarean section, aJer
corticosteroids have been given to improve fetal lung maturation,
which in practice, is aJer 24 to 48 hours (Crowley 1996; Roberts
2013). Others prefer to give corticosteroids, stabilise the woman's
condition and then, if possible, aim to delay delivery. This is
usually known as 'expectant management' (Derham 1989). The
greatest dilemma in deciding when to deliver, is balancing the
risks to mother and baby when the pregnancy is somewhere
between 24 and 34 weeks. Early delivery results in a very premature
baby, which could lead to more neonatal complications, such as
respiratory distress syndrome sometimes called hyaline membrane
disease (diKiculty in breathing and oxygenation), intraventricular
haemorrhage (bleeding into the cavities of the brain), and
necrotising enterocolitis (bleeding into the wall of the bowel due
to a lack of oxygen). Conversely, delaying delivery in an attempt to
allow fetal maturation could place the mother in jeopardy, and at
risk of multisystem organ failure as outlined above. It also prolongs
the time that a fetus is in a potentially hostile in utero environment.
This in turn, will continue to adversely aKect the growth of the
fetus, and may result in an intrauterine death from severe hypoxia,
or an acute event such as an abruption. Although the precise cut-
oKs for gestational age will vary with diKerent settings, before 24
weeks, the child has little chance of survival. AJer 34 weeks, the
prognosis improves, with nearly 100% survival. Between 24 and
34 weeks, mortality decreases with increasing gestational age, but
below 28 weeks, there is considerable risk of survival with severe
disability. A structured review of observational studies found that
expectant care for severe pre-eclampsia, with a prolongation of the
pregnancy by between one and two weeks, was associated with
better outcomes for babies and low risks for the mother. There were
fewer neonatal deaths and complications of prematurity (Magee
2009).
How the intervention might work
The review compared the merits of two management strategies for
sever pre-eclampsia distant from term. It endeavoured to discover
if one of the strategies: interventionist management, i.e. early
delivery, or expectant management, i.e. delaying delivery until
there was a specific maternal or fetal indication to intervene,
conferred an advantage to the baby, mother, or both, without
causing undue risks of morbidity or mortality to one of them.
This means, improving the intact survival rates of preterm babies
without increasing serious morbidity and mortality for the mother.
Why it is important to do this review
This diKicult clinical dilemma occurs relatively frequently in large
units, and currently, decisions are based mainly upon personal
experience rather than good evidence. There is a great need for
reliable data to help inform this decision-making.
Other aspects of care for women with severe pre-eclampsia
are dealt with in other reviews. These include drugs for
lowering very high blood pressure (Duley 2013), prophylactic
anticonvulsants (Duley 2010), and plasma volume expansion
(Duley 1999b). Prevention of pre-eclampsia is covered by reviews
of calcium supplementation (Hofmeyr 2014), antiplatelets (Duley
2007), salt intake (Duley 1999a; Duley 2005), and magnesium
supplementation (Makrides 2014).
O B J E C T I V E S
To evaluate the comparative benefits and risks of a policy of early
delivery by induction of labour or by caesarean section, aJer
suKicient time has elapsed to administer corticosteroids, and allow
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them to take eKect; with a policy of delaying delivery (expectant
care) for women with severe pre-eclampsia between 24 and 34
weeks' gestation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All adequately randomised trials comparing interventionist
(aggressive) with expectant care (delayed delivery) for women
with severe early onset pre-eclampsia. We excluded quasi-random
designs, such as alternate numbers or allocation by the day of the
week. Trials reported in an abstract were eligible for inclusion, as
were cluster-trial designs.
Types of participants
Women with severe pre-eclampsia who were up to, and including,
34 weeks' gestation. Severe pre-eclampsia was defined as:
• high blood pressure (> 140/90 mmHg) on two consecutive
occasions four or more hours apart, plus proteinuria higher than
300 mg/24 hours; or• severe hypertension (blood pressure at least 160 mmHg systolic,
or 110 mmHg diastolic) alone; or• hypertension as defined above, plus one or more of the
following criteria:• severe proteinuria (usually at least 3 g (range 2 g to 5 g)
protein in 24 hours, or 3+ on dipstick);• reduced urinary volume (less than 500 mL in 24 hours), upper
abdominal pain, pulmonary oedema;• neurological disturbances (such as headache, visual
disturbances, and exaggerated tendon reflexes);• impaired liver function tests, high serum creatinine, low
platelets); or• suspected intrauterine growth restriction or reduced
amniotic fluid.
This latter set of criteria reflect the natural history of the disease and
clinical practice when diagnosing severe pre-eclampsia.
Types of interventions
Any comparison of a policy of early elective delivery by induction
of labour or by caesarean section (interventionist management)
with a policy of delayed delivery (expectant management). If
corticosteroids were used in the trial, they should have been used
for both types of care. As the beneficial eKects of a course of
corticosteroids are so important, we excluded any study where
corticosteroids were only administered to one group but not the
other.
Types of outcome measures
Primary outcomes
For the woman• Death• Eclampsia (fitting)• Stroke (brain damage)• HELLP (haemolysis, elevated liver enzymes, and low platelets)
syndrome
• Pulmonary oedema (fluid in the lungs)
For the baby• Stillbirth• Neonatal death• Intraventricular haemorrhage (bleeding in the brain), hypoxic
ischaemic encephalopathy, or both
Secondary outcomes
For the woman• Renal failure (kidney failure)• Liver failure• Cardiac arrest• The need for invasive monitoring, such as central venous
catheterisation (intravenous lines into the great veins around
the heart)• Caesarean section• Placental abruption
For the baby• Low Apgar score at five minutes• Neonatal seizures• Hyaline membrane disease sometimes referred to as
Respiratory Distress Syndrome (stiK lungs)• Pneumothorax (air leaks from the lungs)• Necrotising enterocolitis (bleeding into the bowel wall)• Ventilation (any ventilation, duration of ventilation)• Measures of long-term growth and development, such as
important impairment and cerebral palsy• Small-for-gestational age• Gestation at birth
Use of health service resources• Need for intensive care for the woman• Need for high-dependency care or observation, or both, for the
woman• Length of stay in neonatal intensive care• Admission to neonatal intensive care unit• Surfactant for the baby• Ventilation for the baby
Search methods for identification of studies
The following methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
For this update, we searched Cochrane Pregnancy and Childbirth’s
Trials Register by contacting their Information Specialist (27
November 2017).
The Register is a database containing over 24,000 reports of
controlled trials in the field of pregnancy and childbirth. It
represents over 30 years of searching. For full current search
methods used to populate Pregnancy and Childbirth’s Trials
Register, including the detailed search strategies for CENTRAL,
MEDLINE, Embase, and CINAHL; the list of handsearched journals
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and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the editorial
information about the Cochrane Pregnancy and Childbirth in the
Cochrane Library, and select the ‘Specialized Register’ section from
the options on the leJ side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals, plus
monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activities
described above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a
specific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set that has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searched ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform (ICTRP) for
unpublished, planned, and ongoing trial reports (27 November
2017) using the methods detailed in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Churchill 2013.
For this update, the following methods were used to assess the five
reports that were identified as a result of the updated search.
The following methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Three review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreement through discussion, or if required, we
consulted a fourth review author.
Data extraction and management
We designed a form to extract data. For eligible studies, three
review authors independently extracted the data, using the agreed
form. We resolved discrepancies through discussion, or if required,
we consulted a fourth review author. We entered data into Review
Manager 5 soJware (RevMan 2014), and checked for accuracy.
When information regarding any of the above was unclear, we
contacted authors of the original reports to provide further details.
Assessment of risk of bias in included studies
Three review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). They resolved
disagreements by discussion, or by involving a fourth assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described the method used to generate the allocation sequence
in suKicient detail to allow an assessment of whether it should
produce comparable groups.
For each included study, we assessed the method as being at:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
For each included study, we described the method used to conceal
allocation to interventions prior to assignment, and assessed
whether intervention allocation could have been foreseen in
advance of, or during recruitment, or changed aJer assignment.
We assessed the methods as being at:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study, we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that the
lack of blinding was unlikely to aKect results. We assessed blinding
separately for diKerent outcomes or classes of outcomes.
We assessed the methods as being at:
• low, high, or unclear risk of bias for participants;• low, high, or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study, we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for diKerent
outcomes or classes of outcomes.
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We assessed methods used to blind outcome assessment as being
at:
• low, high, or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For each included study, and for each outcome or class of
outcomes, we described the completeness of data, including
attrition and exclusions from the analysis. We stated whether
attrition and exclusions were reported, and the numbers included
in the analysis at each stage (compared with the total randomised
participants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where suKicient information was reported, or could
be supplied by the trial authors, we planned to re-include missing
data in the analyses that we undertook.
We assessed methods as being at:
• low risk of bias (e.g. no missing outcome data; missing outcome
data balanced across groups);• high risk of bias (e.g. numbers or reasons for missing
data imbalanced across groups; ‘as treated’ analysis done
with substantial departure of intervention received from that
assigned at randomisation);• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
For each included study, we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as being at:
• low risk of bias (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review were reported);• high risk of bias (where not all the study’s prespecified outcomes
were reported; one or more reported primary outcomes
were not prespecified; outcomes of interest were reported
incompletely, and so could not be used; study failed to include
results of a key outcome that would have been expected to have
been reported);• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by
(1) to (5) above)
For each included study, we described any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at
high risk of bias, according to the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
With reference to (1) to (6) above, we had planned to assess
the likely magnitude and direction of the bias and whether we
considered it was likely to have an impact on the findings. In future
updates, we will explore the impact of the level of bias through
undertaking sensitivity analyses (Sensitivity analysis).
Assessment of the quality of the evidence using the GRADE
approach
For this update, we assessed the quality of the evidence using the
GRADE approach, as outlined in the GRADE Handbook, in order to
assess the quality of the body of evidence relating to the following
outcomes for the main comparison, interventionist care versus
expectant (GRADE Handbook).
For the woman• Death• Eclampsia (fitting)• Stroke (brain damage)• HELLP (haemolysis, elevated liver enzymes and low platelets)
syndrome• Pulmonary oedema (fluid in the lungs)
For the baby• Perinatal mortality• Intraventricular haemorrhage (bleeding in the brain), hypoxic
ischaemic encephalopathy, or both
We used the GRADEpro GDT to import data from Review Manager
5.3 in order to create ’Summary of findings’ tables (GRADEpro GDT;
RevMan 2014). We produced a summary of the intervention eKect
and a measure of quality for each of the above outcomes, using
the GRADE approach. The GRADE approach uses five considerations
(study limitations, consistency of eKect, imprecision, indirectness,
and publication bias) to assess the quality of the body of evidence
for each outcome. The evidence can be downgraded from high
quality by one level for serious (or by two levels for very serious)
limitations, depending on assessments for risk of bias, indirectness
of evidence, serious inconsistency, imprecision of eKect estimates,
or potential publication bias.
Measures of treatment e;ect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean diKerence if outcomes were measured in
the same way between trials. We used the standardised mean
diKerence to combine trials that measured the same outcome, but
used diKerent methods.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion. If we
identify cluster-randomised trials in future updates, we will include
them in the analyses along with individually-randomised trials.
We will adjust their sample sizes, using the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions,
using an estimate of the intracluster correlation co-eKicient (ICC)
derived from the trial (if possible), from a similar trial, or from a
study of a similar population. If we use ICCs from other sources, we
will report this, and conduct sensitivity analyses to investigate the
eKect of variation in the ICC. If we identify both cluster-randomised
trials and individually-randomised trials, we plan to synthesise the
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relevant information. We will consider it reasonable to combine the
results from both if there is little heterogeneity between the study
designs, and the interaction between the eKect of the intervention
and the choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit,
and perform a sensitivity analysis to investigate the eKects of the
randomisation unit.
Cross-over trials 
Cross-over trials are not a valid study design for this review.
Dealing with missing data
For included studies, we noted levels of attrition. In future updates,
if more eligible studies are included, we will explore the impact
of including studies with high levels of missing data in the overall
assessment of treatment eKect by using sensitivity analyses.
For all outcomes, we carried out analyses, as far as possible,
on an intention-to-treat basis, i.e. we attempted to include all
participants randomised to each group in the analyses. The
denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes were known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
Tau2, I2, and Chi2 statistics. We regarded heterogeneity as
substantial if I2 was greater than 30%, and either Tau2 was greater
than zero, or there was a low P value (less than 0.10) in the Chi2 test
for heterogeneity. If we identified substantial heterogeneity (above
30%), we had planned to explore it by prespecified subgroup
analysis, assuming we had suKicient data.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager 5 soJware
(RevMan 2014). We used fixed-eKect meta-analysis to combine data
where it was reasonable to assume that studies were estimating the
same underlying treatment eKect: i.e. where trials were examining
the same intervention, and the trials’ populations and methods
were judged suKiciently similar.
If there was clinical heterogeneity suKicient to expect that
the underlying treatment eKects diKered between trials, or
if substantial statistical heterogeneity was detected, we used
random-eKects meta-analysis to produce an overall summary if
an average treatment eKect across trials was considered clinically
meaningful. The random-eKects summary was treated as the
average of the range of possible treatment eKects, and we had
planned to discuss the clinical implications of treatment eKects
diKering between trials. If the average treatment eKect is not
clinically meaningful, we will not combine trials. If we used random-
eKects analyses, we presented the results as the average treatment
eKect with 95% confidence intervals, and the estimates of Tau2 and
I2.
Subgroup analysis and investigation of heterogeneity
In future updates, if we identify substantial heterogeneity and
have suKicient data, we will investigate it using subgroup and
sensitivity analyses. We will consider whether an overall summary
is meaningful, and if it is, use random-eKects analysis to produce it.
We plan to carry out the following subgroup analyses based on:
1. gestation at trial entry: 24 to 28 weeks' gestation; 29 to 34 weeks'
gestation; gestation mixed or unknown;
2. suspected intrauterine growth restriction at trial entry:
suspected intrauterine growth restriction; no suspected
intrauterine growth restriction; mixed or unknown.
We will explore the following primary outcomes in subgroup
analyses.
For the woman• Death• Eclampsia (fitting)• Stroke (brain damage)• HELLP syndrome• Pulmonary oedema
For the baby• Stillbirth• Neonatal death• Intraventricular haemorrhage
We will assess diKerences between subgroups using interaction
tests available in Review Manager 5.
Sensitivity analysis
In future updates, if we identify more studies to include in analyses,
we plan to carry out sensitivity analyses to explore the eKect of risk
of bias assessed by concealment of allocation, high attrition rates,
or both, with studies at high risk of bias being excluded from the
analyses in order to assess whether this makes any diKerence to the
overall result.
R E S U L T S
Description of studies
Results of the search
See: Figure 1.
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Figure 1.   Study flow diagram
 
We assessed four new trial reports and also reassessed one ongoing
study. We included two new trials in five reports (Duvekot 2015;
Vigil-De Gracia 2013).
We included four trials in the previous version of this review
(Mesbah 2003; Odendaal 1990; Sibai 1994; Thornton 2004 (GRIT)).
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Included studies
We included six trials with a total of 748 women in this review.
The Thornton 2004 (GRIT) trial contributed 262 participants to this
review, which is just under half of the participants recruited to this
trial, which compared management strategies for women with a
growth restricted fetus. The study was jointly funded by the UK
Medical Research Council (MRC), the European Union Concerted
Action, and the Dutch Princess Beatrix Foundation. There were no
declarations of interest, and it took place from November 1993
to March 2001. The most recent study was the largest, with 267
women randomised; it was conducted between August 2010 and
August 2012 (Vigil-De Gracia 2013). This trial was carried out in Latin
America, and was funded by the Marjorie Milham Research Fund,
Pennsylvania Hospital, Perelman School of Medicine, University of
Pennsylvannia. The trial only recruited women between 28 and
33 weeks' gestation. Participants below 28 weeks were excluded,
because it was felt that the neonatal care provided was too poor,
due to limited resources in some units, which may have restricted
generalisablity. There were no declarations of interest by the
researchers. The study by Mesbah and colleagues recruited women
between January 2001 and May 2002. The funding sources were
not disclosed and there were no statements about declarations of
interest. The study was judged to be at high risk of bias due to
missing outcome data (Mesbah 2003). The oldest of the trials was
by Odendaal, and published in 1990 (Odendaal 1990). Recruitment
took place between January 1986 and January 1988. The study was
carried out in South Africa, and funded by the South African Medical
Research Council. There were no declarations of interest made by
the researchers. The fiJh trial was carried out in the USA (Sibai
1994). The trial recruited 95 women from January 1991 to July 1993.
The funding source was not stated, and there were no declarations
of interest. The sixth trial was conducted in the Netherlands, in
2015, and has only been reported as a poster. No further details
were obtained from the authors (Duvekot 2015).
Setting
Three trials were multi-centre: one was UK based and involved
69 hospitals in 13 European countries (Thornton 2004 (GRIT)), one
was based in Latin America, and was carried out in eight tertiary
hospitals in Latin America (Vigil-De Gracia 2013), and a third was
based in nine hospitals in the Netherlands (Duvekot 2015). The
other three trials were single-centre trials, based in Egypt (Mesbah
2003), South Africa (Odendaal 1990), and the USA (Sibai 1994).
Participants
One trial included 548 pregnant women with fetal growth
restriction, between 24 and 36 weeks' gestation, an umbilical
artery Doppler waveform recorded and clinical uncertainty about
whether immediate delivery was indicated (Thornton 2004 (GRIT)).
We included a subset of women from this trial, who were at
less than or equal to 34 weeks' gestation (N = 262), and had
severe pre-eclampsia. Vigil-De Gracia 2013 included 267 women
who had severe pre-eclampsia, and were between 28 and 33
weeks' gestation. Women with the condition, who were at less that
28 weeks' gestation were excluded from this trial. Mesbah 2003
included 30 women with severe pre-eclampsia between 28 and 33
weeks' gestation; Odendaal 1990 included 38 women with severe
pre-eclampsia between 28 and 34 weeks' gestation; and Sibai 1994
included 95 women with severe pre-eclampsia at 28 to 32 weeks'
gestation. In four trials, it was explicitly stated that women with an
immediate indication for delivery in the maternal or fetal interest
were excluded (Mesbah 2003; Odendaal 1990; Sibai 1994; Vigil-De
Gracia 2013). In one trial, this exclusion was implicit, since the trial
entry criterion was obstetrician uncertainty about the benefit of
immediate or delayed delivery (Thornton 2004 (GRIT)). One trial
included 56 women between 28 and 34 weeks of gestation with
severe pre-eclampsia, with or without HELLP (haemolysis, elevated
liver enzymes and low platelets) syndrome (Duvekot 2015). The trial
stopped early due to poor recruitment.
Interventions
In five trials, women had a 24- to 48-hour period of stabilisation,
during which they were given steroids to accelerate fetal lung
maturity, and if necessary, magnesium sulphate to prevent
seizures, and antihypertensives to lower blood pressure. If they
continued to meet the eligibility criteria at the end of this period,
they were then randomised. They were either randomised to
the interventionist group, which involved immediate delivery by
caesarean section or induction, or to the expectant management
group, who were managed with hospitalisation and intensive
maternal and fetal monitoring. Earlier delivery in this expectant
group was implemented if either the maternal or fetal condition
deteriorated, as determined by prespecified criteria. In one trial,
women in the intervention group were delivered immediately, and
the control group were given temporising management (Duvekot
2015).
Outcomes
The main outcomes in all studies included maternal, perinatal,
and neonatal morbidity and mortality outcomes. Only one trial
included long-term outcomes; measures of long-term growth and
development at two years (Thornton 2004 (GRIT)).
For further details see Characteristics of included studies.
Excluded studies
We excluded two trials as they did not meet the inclusion criteria of
the review (Gruppo di Studio1998; Langenveld 2011). In both trials,
the women did not have severe pre-eclampsia.
See table of Characteristics of excluded studies.
Risk of bias in included studies
Overall, we judged three trials to be at low risk of bias (Sibai
1994; Thornton 2004 (GRIT); Vigil-De Gracia 2013), two were unclear
(Duvekot 2015; Odendaal 1990), and one was at high risk of bias
(Mesbah 2003).
See Figure 2 and Figure 3 for summaries of 'Risk of bias' assessment.
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Figure 2.   'Risk of bias' graph: review authors' judgements about each risk of bias item, presented as percentages
across all included studies
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Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study
 
Allocation
In two studies, the methods used for randomisation and
concealment of allocation were not described (Duvekot 2015;
Odendaal 1990); in another, the description of concealment of
allocation was unclear, and we were uncertain if this was adequate
(Vigil-De Gracia 2013), and in the other three trials, the methods
of both randomisation and concealment were adequate (Mesbah
2003; Sibai 1994; Thornton 2004 (GRIT)).
Blinding
Blinding of participants, personnel, or outcome assessors was
not described in four of the trials (Duvekot 2015; Mesbah 2003;
Odendaal 1990; Sibai 1994). One study was described as open
label and recognised that the outcomes were not concealed (Vigil-
De Gracia 2013). Blinding of outcome assessment for long-term
outcomes, such as GriKiths assessment, was reported in one trial
(Thornton 2004 (GRIT)).
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Incomplete outcome data
In two trials, all women appeared to have been accounted for in
the results (Sibai 1994; Vigil-De Gracia 2013). In one trial, individual
patient data for a subset of women with severe pre-eclampsia
were provided by the authors of the original trial, and it was not
possible to tell how complete this dataset was (Thornton 2004
(GRIT)). In another trial, it was not clear, from the results tables,
how many were included in the analyses (Odendaal 1990). In
Duvekot 2015, it stated that analysis was by intention-to-treat, and
numbers randomised appeared to be accounted for in the analyses,
but the trial was stopped early because of low recruitment. In
one trial, 41 women were recruited, but 11 (27%) were judged
to be too compromised for expectant management, and were
delivered by caesarean section; and aJer randomisation, five
patients appear to be missing from the results table 2 (Mesbah
2003).                                                             
Selective reporting
All expected outcomes appear to have been reported in four trials
(Mesbah 2003; Odendaal 1990; Sibai 1994; Thornton 2004 (GRIT)).
In one trial, some of the outcomes reported in the trial registry
record and protocol were not reported, but this was probably due
to the trial stopping early, rather than selective reporting (Duvekot
2015). In one trial, the trial was registered, however the planned
secondary outcomes were listed only as 'Perinatal complications
and maternal complications' (Vigil-De Gracia 2013).
Other potential sources of bias
In two studies, baseline characteristics were similar between
groups and no other sources of bias were apparent (Odendaal 1990;
Sibai 1994). In one study, other bias may have been introduced, as
only a subset of the original randomised sample provided data for
analysis, but this was not clear (Thornton 2004 (GRIT)). In one study,
the severe group was excluded from the study, and no baseline
characteristics were described for this group of patients (Mesbah
2003).    In one study, three women in the expectant management
group were excluded from the analyses. Two women refused to
remain in hospital, and one woman received incorrect treatment
due to physician error in Vigil-De Gracia 2013. In one study, the trial
stopped early due to low recruitment (Duvekot 2015).
E;ects of interventions
See: Summary of findings for the main comparison
Interventionist care compared to expectant (delayed delivery) care
for severe pre-eclampsia for severe pre-eclampsia between 24 and
34 weeks' gestation
1. Interventionist care versus expectant (delayed delivery)
care for severe pre-eclampsia
Primary outcomes
Three studies (415 women) reported on primary outcomes of
relevance to the woman. Two studies reported on maternal death,
and there were no maternal deaths in either study (0/159 vs
0/161; eKect not estimable; two studies, 320 women; low-quality
evidence; Analysis 1.1). Due to very low-quality evidence from
two studies, it was unclear whether interventionist care reduced
eclampsia (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.06 to
15.58; two studies, 359 women; Analysis 1.2), or pulmonary oedema
(RR 0.45, 95% CI 0.07 to 3.00; two studies, 415 women; Analysis 1.3).
Low-quality evidence from two studies suggested little or no clear
diKerence between the interventionist and expectant care groups
for HELLP syndrome (RR 1.09, 95% CI 0.62 to 1.91; two studies, 359
women; Analysis 1.4). Stroke was not an outcome reported in any
trial.
For the baby, there was insuKicient evidence for any reliable
conclusions about the eKects on stillbirth (RR 0.30, 95% CI 0.07
to 1.23; five trials; 692 women, with 700 babies), perinatal death
(RR 1.11, 95% CI 0.62 to 1.99; three studies, 343 infants; low-
quality evidence), or neonatal death aJer delivery (RR 1.32, 95%
CI 0.80 to 2.19; five trials; 485 babies; Analysis 1.6. More babies
whose mothers had been allocated to the interventionist group had
intraventricular haemorrhage (RR 1.94, 95% CI 1.15 to 3.29; two
trials; 537 women; moderate-quality evidence; Analysis 1.7).
Secondary outcomes
Women allocated to the interventionist group were no more likely
to have a caesarean section than those allocated to an expectant
policy (random-eKects, average RR 1.01, 95% CI 0.91 to 1.12;
heterogeneity: Tau2 = 0.01, I2 = 63%; six trials; 745 women; Analysis
1.8). There were no clear diKerences between the two management
strategies for renal failure (RR 0.32, 95% CI 0.05 to 1.99; three trials;
397 women; Analysis 1.9), or placental abruption (RR 0.42, 95% CI
0.18 to 0.96; four trials; 453 women; Analysis 1.10). Liver failure,
cardiac arrest, and the need for invasive monitoring for the woman
were not reported in any of the trials.
This review suggested that an interventionist policy of care
may be associated with increased morbidity for the baby. For
example, those babies whose mothers had been allocated to the
interventionist group had more hyaline membrane disease (RR
2.30, 95% CI 1.39 to 3.81; two trials; 133 women; Analysis 1.11),
were more likely to require ventilation (RR 1.50, 95% CI 1.11 to 2.02;
two trials; 300 women; Analysis 1.12), and had a lower gestation
at birth (random-eKects, mean diKerence (MD) -9.91 days, 95% CI
-16.37 to -3.45 days; heterogeneity: Tau2 = 31.74, I2 = 76%; four
trials; 425 women; Analysis 1.13). There was no clear diKerence
between the allocated groups in the risk of developing necrotising
enterocolitis, (RR 1.79, 95% CI 0.84 to 3.81; four trials; 670 women;
Analysis 1.14). Babies whose mothers had been allocated to the
interventionist policy were less likely to be small-for-gestational
age (RR 0.38, 95% CI 0.24 to 0.61; three trials; 400 women; Analysis
1.15). In one trial (262 women), there were no clear diKerences
between the two management strategies for low Apgar score at five
minutes (Analysis 1.16), neonatal seizures (Analysis 1.17), and three
measures of long-term growth and development; cerebral palsy
(Analysis 1.18), poor hearing, use of hearing aid (Analysis 1.19), and
impaired vision (Analysis 1.20).
Babies whose mothers had been allocated to the interventionist
group were no more likely to be admitted to neonatal intensive
care than the expectant management group (average RR 1.19, 95%
CI 0.89 to 1.60; heterogeneity: Tau2 = 0.05; I2 = 84%; three trials,
400 women Analysis 1.21), or have a longer stay in the neonatal
intensive care unit (random-eKects, MD -7.38 days, 95% CI -0.45 to
15.20 days; heterogeneity: Tau2 = 40.93, I2 = 85%; three trials, 400
women; Analysis 1.22), than those allocated to receive an expectant
policy. Other outcomes on the use of health service resources were
not reported in any of the trials (need for intensive care for the
woman; need for high-dependency care or observation, or both, for
the woman; surfactant for the baby).
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D I S C U S S I O N
Timing the delivery of a very premature infant in the presence
of severe pre-eclampsia is a diKicult clinical decision. When the
mother's life is in danger, there is no doubt that delivery is the
only correct course of action. This situation is rare. More frequently,
if the pregnancy is continued, the risks of maternal morbidity or
intrauterine fetal demise have to be constantly balanced against the
hazards of prematurity to the fetus if delivered. Most obstetricians
would probably be cautious, and expedite delivery in favour of
the outcome for the mother, and the guarantee of a live baby at
delivery. What is not clear, is to what level, if at all, this adversely
aKects the baby.
Only the GRIT study prespecified fetal assessment parameters as
entry criteria into the trial (Thornton 2004 (GRIT)). The other studies
used fetal assessment to trigger delivery if there was evidence of
significant compromise. Therefore, it is not possible to compare the
trials for the condition of the fetuses on trial entry. However, it is
unlikely that there would have been any clinical diKerences where
this was not formally assessed at trial entry. If there were signs
of imminent fetal demise, then the women would not have been
randomised into the trials. But there is the potential for unseen
bias, and future trials must include a formal assessment of fetal
well-being on trial entry.
Currently, there were insuKicient data to justify any of our
prespecified subgroup analyses. These will be included in future
updates of this review, when larger trials become available.
There were insuKicient data for reliable conclusions from this
review. However, the evidence suggests that short-term morbidity
for the baby may be reduced by a policy of expectant care. This
is perhaps surprising, given that expectant management increases
the length of time a fetus is exposed to severe pre-eclampsia, with
the potential to adversely aKect fetal growth and well-being. In
fact, this is oJen stated as a reason for intervention. The results of
this review suggested this may be otherwise. While the babies in
the expectant management group were smaller, their short-term
outcomes were better. Before this policy can be recommended
in clinical practice, further evidence is required to demonstrate
whether there is truly a short-term benefit for the baby without any
increase in mortality, and if so, that it continues in the longer term.
Reassurance is also needed that there is no increase in morbidity
for the mother.
Summary of main results
There was insuKicient evidence on stillbirth or death aJer delivery
to draw reliable conclusions about the eKects of either policy
for care. However, there was some evidence from this review to
suggest that a policy of prolonging pregnancy reduced serious
morbidity in the neonatal period of life. Fewer babies had an
intraventricular haemorrhage or hyaline membrane disease, and
there were reduced levels of ventilation for those allocated to
expectant management. Babies whose mothers were allocated to
expectant care were no more likely to be admitted to the neonatal
intensive care unit, and when admitted, were more likely to stay
there for shorter periods of time. There were insuKicient data to
draw any conclusions about the comparative eKects of these two
policies of care on the mothers' health. Even taken together, these
studies did not have suKicient sample size to demonstrate small to
moderate diKerences in maternal outcome.
Overall completeness and applicability of evidence
There was insuKicient evidence from this review to recommend a
particular management policy for this area of obstetric care. The
numbers of participants in the trials was too small to be able to
demonstrate diKerences in most significant (primary) outcomes,
and where diKerences were found, there was a considerable level
of heterogeneity, or the contribution was mainly from one trial. The
same was true for the analysis of the secondary outcome measures.
Quality of the evidence
We judged three of the trials included in the review to be at
unclear risk of both performance and detection bias. It was not
possible to blind personnel and participants to interventions, but
most outcomes were objective outcomes, and were unlikely to
be aKected by blinding, e.g. death, eclampsia. One study was
also judged to be at risk of attrition bias (Mesbah 2003). The
Thornton 2004 (GRIT) trial was not originally designed to examine
severe pre-eclampsia. It looked at interventionist versus expectant
management for babies with growth restriction. A by-product of
this study, was that a subset of women also had severe pre-
eclampsia, and it was these women who we included in the review.
Overall, we judged three trials to have a low risk of bias (Sibai
1994; Thornton 2004 (GRIT); Vigil-De Gracia 2013), two as unclear
(Duvekot 2015; Odendaal 1990), and one at a high risk of bias
(Mesbah 2003).
We also assessed the quality of the evidence for seven key
maternal and baby outcomes, using the GRADE approach (see
Summary of findings for the main comparison). For eclampsia
and pulmonary oedema, we judged the evidence to be very low-
quality, downgraded due to concerns relating to limitations in
study design and imprecision, due to small sample sizes, small
number of events, and wide confidence intervals crossing the line
of no eKect. For maternal death, HELLP (haemolysis, elevated liver
enzymes and low platelets) syndrome, and perinatal mortality, we
judged the evidence to be low-quality, due again to limitations
in study design and imprecision. We judged the evidence for
one outcome, intraventricular haemorrhage or hypoxic ischaemic
encephalopathy, to be of moderate quality, downgraded due to
limitations in study design.
Potential biases in the review process
We took steps to minimise bias, although we are aware that bias
may be present in our review. Two review authors independently
assessed studies for eligibility and extracted the data as necessary.
We resolved discrepancies through discussion, or if required,
we consulted a third review author. Two review authors also
independently performed GRADE assessments, and resolved
discrepancies though discussion. One of the review authors (J
Thornton) was the Principle Investigator for one of the included
trials (Thornton 2004 (GRIT)). To remove the potential for bias, the
GRIT trial data were supplied directly to two other review authors
from the trial statistician. J Thornton had no dealings with the
acquisition, preparation, or analysis of the GRIT trial data in this
review.
Agreements and disagreements with other studies or
reviews
There were no other systematic reviews of delivery timing in
pregnancies complicated by pre-eclampsia before 34 weeks.
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
16
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
However, our findings were consistent with the recommendations
of all the expert guidelines reviewed by Gillon 2014, which all
recommend expectant management before 34 weeks, in the
absence of uncontrollable hypertension, maternal organ failure, or
severe fetal compromise.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
These data were insuKicient to reach any firm conclusions about
the comparative eKects of these alternative strategies for the care of
women with severe, early onset pre-eclampsia, in the absence of an
over-riding maternal or fetal indication for delivery. Nevertheless,
the apparent increase in some measures of neonatal morbidity
associated with interventionist care suggested that early delivery
would need to be justified by a realistic expectation of harm to
the mother if the pregnancy was continued. The current advice
from both the National Insitute for Clinical Excellence and the
World Health Organization seems to reflect this interpretation of
the evidence to date, as both recommend deferring delivery until
there are clear signs of fetal compromise, inability to control the
maternal blood pressure, or evidence of maternal organ failure
(NICE 2010; WHO 2011).
Implications for research
Larger trials are needed to confirm whether the benefits for the
child associated with a policy of expectant care are real, and
without significant risks, and to provide reassurance that there is
no increase in risk of morbidity or mortality for the mother.
A C K N O W L E D G E M E N T S
The National Institute for Health Research (NIHR) is the largest
single funder of the Cochrane Pregnancy and Childbirth Group. The
views and opinions expressed therein are those of the authors and
do not necessarily reflect those of the NIHR, NHS or the Department
of Health.
We thank Leanne Jones for her contribution as an author in the
previous update (Churchill 2013), and Leanne Jones and Anna
Cuthbert for preparing the GRADE 'Summary of findings' table for
this update.
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
R E F E R E N C E S
 
References to studies included in this review
Duvekot 2015 {published data only}
*  Duvekot J, Bax C, Bloemenkamp K, Dijk P, Van D, Franssen M,
et al. Temporizing management versus termination of
pregnancy in women with severe preeclampsia at 28-34 weeks
(TOTEM-Trial). American Journal of Obstetrics and Gynecology
2015;212(1 Suppl 1):S246.
Duvekot JJ, Steegers EAP, Hop WCJ, Franx A, van der Post JAM,
van Wassenaer A, et al. TOTEM study (temporise or terminate
pregnancy in women with severe preeclampsia at 28-34 weeks):
a study protocol. Pregnancy Hypertension 2011;1 Suppl 1:295.
NTR2986. Expectant or active management in women with
severe preeclampsia at 28-34 weeks. Available at trialregister.nl/
trialreg/admin/rctview.asp?TC=2986 (first received 11 July
2011).
Mesbah 2003 {published data only}
Mesbah EMM. Severe preterm preeclampsia: aggressive or
expectant management?. Medical Journal of Cairo University
2003;71(1):175-82.
Odendaal 1990 {published data only}
Odendaal HJ, Pattinson RC. Active or conservative treatment of
severe preeclampsia - a randomized control trial. Proceedings
of 37th Annual Meeting of the Society for Gynecologic
Investigation; 1990 March 21-24; St Louis, USA. 1990:359.
*  Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ.
Aggressive or expectant management for patients with severe
preeclampsia between 28-34 weeks' gestation: a randomized
controlled trial. Obstetrics & Gynecology 1990;76:1070-5.
Sibai 1994 {published data only}
Sibai BM, Mercer BM, SchiK E, Friedman SA. Aggressive versus
expectant management of severe preeclampsia at 28 to 32
weeks' gestation: a randomized controlled trial. American
Journal of Obstetrics and Gynecology 1994;171:818-22.
Thornton 2004 (GRIT) {published data only}
GRIT Study Group. A randomised trial of timed delivery for the
compromised preterm fetus: short term outcomes and Bayesian
interpretation. BJOG: An International Journal of Obstetrics and
Gynaecology 2003;110:27-32.
Hornbuckle J, Thornton JG, Vail A, GRIT SG. The Growth
Restriction Intervention Trial (GRIT): interim progress report.
Women's Health - into the new millennium. Proceedings of
the 4th International Scientific Meeting of the Royal College of
Obstetricians and Gynaecologists; 1999 October 3-6; Cape Town
South Africa. RCOG, 1999:76.
Schneider KTM, Brocker J, Thornton J. A randomised
intervention of timed delivery for the compromised preterm
fetus [Randomisierte Intervention zur Optimierung des
Entbindungszeitpunktes bei kompromittierten IUGR-Feten
(Euro-GRIT)]. Geburtshilfe und Frauenheilkunde 2000;60 Suppl
1:S72.
*  Thornton JG, Hornbuckle J, Vail A, Spiegelhalter DJ, Levene M,
GRIT study group. Infant wellbeing at 2 years of age in the
Growth Restriction Intervention Trial (GRIT): multicentred
randomised controlled trial. Lancet 2004;364:513-20.
Walker DM, Marlow N, Upstone L, Gross H, Hornbuckle J,
Vail A, et al. The Growth Restriction Intervention Trial: long-
term outcomes in a randomized trial of timing of delivery in
fetal growth restriction. American Journal of Obstetrics and
Gynecology 2011;204(1):34.e1-9.
Vigil-De Gracia 2013 {published data only}
NCT01164852. Expectant management of severe preeclampsia
at 28 to 33 week`s gestation: a randomized controlled trial.
Available at clinicaltrials.gov/ct2/show/NCT01164852 (first
received 19 July 2010).
*  Vigil-De Gracia P, Reyes Tejada O, Calle Minaca A, Tellez G,
Chon VY, Herrarte E, et al. Expectant management of severe
preeclampsia remote from term: the MEXPRE Latin Study, a
randomized, multicenter clinical trial. American Journal of
Obstetrics and Gynecology 2013;209(5):425.e1-8.
 
References to studies excluded from this review
Gruppo di Studio1998 {published data only}
Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus
expectant management in mild to moderate hypertension
in pregnancy. British Journal of Obstetrics and Gynaecology
1998;105:718-22.
Langenveld 2011 {published data only}
Langenveld J, Broekhuijsen K, van Baaren GJ, van Pampus MG,
van Kaam AH, Groen H, et al. Induction of labour versus
expectant monitoring for gestational hypertension or mild pre-
eclampsia between 34 and 37 weeks' gestation (HYPITAT-II):
A multicentre, open-label randomised controlled trial. BMC
Pregnancy and Childbirth 2011;11:50.
 
Additional references
Brown 2001
Brown MA, Lindheimer MD, de Swiet M, van Assche A,
Moutquin J-M. The classification and diagnosis of the
hypertensive disorders of pregnancy: statement from the
International Society for the Study of Hypertension in
Pregnancy. Hypertension in Pregnancy 2001;20:ix-xiv.
Crowley 1996
Crowley P. Prophylactic corticosteroids for preterm birth.
Cochrane Database of Systematic Reviews 1996, Issue 1. [DOI:
10.1002/14651858.CD000065.pub2]
Davey 1988
Davey DA, MacGillivray I. The classification and definition of
the hypertensive disorders in pregnancy. American Journal of
Obstetrics and Gynecology 1988;158:892-8.
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
18
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Derham 1989
Derham RJ, Hawkins DF, deVries LS, Aber VR, Elder MG.
Outcome of pregnancies complicated by severe hypertension
and delivered before 34 weeks: stepwise logistic regression
analysis of prognostic factors. British Journal of Obstetrics and
Gynaecology 1989;96:1173-81.
Duley 1999a
Duley L, Henderson-Smart D. Reduced salt intake compared
to normal dietary salt, or high intake, in pregnancy.
Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI:
10.1002/14651858.CD001687]
Duley 1999b
Duley L, Williams J, Henderson-Smart DJ. Plasma volume
expansion for treatment of pre-eclampsia. Cochrane
Database of Systematic Reviews 1999, Issue 4. [DOI:
10.1002/14651858.CD001805]
Duley 2005
Duley L, Henderson-Smart D, Meher S. Altered dietary
salt for preventing pre-eclampsia, and its complications.
Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI:
10.1002/14651858.CD005548]
Duley 2007
Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet
agents for preventing pre-eclampsia and its complications.
Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI:
10.1002/14651858.CD004659.pub2]
Duley 2009
Duley L, Henderson-Smart DJ, Walker GJA. Interventions for
treating pre-eclampsia and its consequences: generic protocol.
Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI:
10.1002/14651858.CD007756]
Duley 2010
Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D.
Magnesium sulphate and other anticonvulsants for women with
pre-eclampsia. Cochrane Database of Systematic Reviews 2010,
Issue 11. [DOI: 10.1002/14651858.CD000025.pub2]
Duley 2013
Duley L, Meher S, Jones L. Drugs for treatment of
very high blood pressure during pregnancy. Cochrane
Database of Systematic Reviews 2013, Issue 7. [DOI:
10.1002/14651858.CD001449.pub3]
Gillon 2014
Tessa ER, Gillon TER, Pels A, Von Dadleszen P, MacDonell K,
Magee L. Hypertensive disorders of pregnancy: a systematic
review of international clinical practice guidelines. PLoS ONE 1
December 2014;9:e113715.
GRADE Handbook
Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s).
Handbook for grading the quality of evidence and the strength
of recommendations using the GRADE approach (updated
October 2013). GRADE Working Group, 2013. Available from
gdt.guidelinedevelopment.org/app/handbook/handbook.html.
GRADEpro GDT [Computer program]
McMaster University (developed by Evidence Prime). GRADEpro
GDT. Version accessed prior to 25 September 2018. Hamilton
(ON): McMaster University (developed by Evidence Prime), 2015.
Higgins 2011
Higgins JPT, Green S, editor(s). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Hofmeyr 2014
Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L, Torloni MR.
Calcium supplementation during pregnancy for preventing
hypertensive disorders and related problems. Cochrane
Database of Systematic Reviews 2014, Issue 6. [DOI:
10.1002/14651858.CD001059.pub4]
Magee 2009
Magee LA, Yong PJ, Espinosa V, Cote AM, Chen I,
von Dadelszen P. Expectant management of severe pre-
eclampsia remote from term: a structured systematic review.
Hypertension in Pregnancy 2009;28(3):312-47.
Makrides 2014
Makrides M, Crosby DD, Bain E, Crowther CA.
Magnesium supplementation in pregnancy. Cochrane
Database of Systematic Reviews 2014, Issue 4. [DOI:
10.1002/14651858.CD000937.pub2]
Morris 2012
Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD. Diagnostic
accuracy of spot urinary protein and albumin to creatinine
ratios for detection of significant proteinuria or adverse
pregnancy outcome in patients with suspected pre-eclampsia:
systematic review and meta-analysis. BMJ (Clinical research ed.)
2012;345:e4342. [PUBMED: 22777026]
NICE 2010
National Collaborating Centre for Women’s and Children’s
Health. Hypertension in pregnancy: the management of
hypertensive disorders during pregnancy (NICE Clinical
Guidelines, No. 107). London: RCOG Press, 2010.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration. Review
Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.
Roberts 2013
Roberts D, Brown J, Medley N, Dalziel SR. Antenatal
corticosteroids for accelerating fetal lung maturation for women
at risk of preterm birth. Cochrane Database of Systematic
Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD004454.pub3]
Sibai 1984
Sibai BM, Spinnato JA, Watson DL, Hill GA, Anderson GD.
Pregnancy outcome in 303 cases with severe preeclampsia.
Obstetrics & Gynecology 1984;64:319-25.
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
19
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
von Dadelszen 2011
von Dadelszen P, Payne B, Li J, Ansermino MJ, Broughton FP,
Cote A, et al. Prediction of adverse maternal outcomes in pre-
eclampsia: development and validation of the full PIERS model.
Lancet 2011;377(9761):219-27.
WHO 2011
World Health Organization. WHO recommendations
for prevention and treatment of pre-eclampsia and
eclampsia. www.who.int/reproductivehealth/publications/
maternal_perinatal_health/9789241548335/en/ 2011:1-48.
 
References to other published versions of this review
Churchill 2002
Churchill D, Duley L. Interventionist versus expectant
care for severe pre-eclampsia before term. Cochrane
Database of Systematic Reviews 2002, Issue 3. [DOI:
10.1002/14651858.CD003106]
Churchill 2013
Churchill D, Duley L, Thornton JG, Jones L. Interventionist
versus expectant care for severe pre-eclampsia between 24 and
34 weeks' gestation. Cochrane Database of Systematic Reviews
2013, Issue 7. [DOI: 10.1002/14651858.CD003106.pub2]
Duley 1995
Duley L. Aggressive vs expectant management of pre-eclampsia.
In: Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C, editor(s).
Pregnancy and Childbirth Module. In: The Cochrane Database
of Systematic Reviews (database on disk and CDROM). The
Cochrane Collaboration; Issue 2, Oxford: Update SoJware; 1995.
 
* Indicates the major publication for the study
 
C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Multi-centre randomised controlled trial
Setting: 19 hospitals in the Netherlands
Participants 56 women from nine hospitals were randomised.
Inclusion criteria: Women between 28+0 and 34+0 weeks of gestation after admission for severe pre-
eclampsia with or without HELLP syndrome
Interventions Immediate delivery (N = 26): delivery 48 hours after admission
Expectant management (N= 30): described as 'temporising management'
Outcomes Primary outcome: composite major maternal and neonatal morbidity and mortality; maternal long-
term outcome defined as persistent morbidity
Women: median prolongation of labour; maternal death; pulmonary edema; placental abruption, en-
cephalopathy or eclampsia, ARDS (Acute Respiratory Distress Syndrome), cerebrovascular incident, liv-
er haematoma or liver rupture, acute fatty liver of pregnancy, severe renal insufficiency, thromboem-
bolism
Baby: neonatal morbidity; neonatal death; birthweight; long-term neonatal outcome using Bailey-3 as-
sessment
Notes The trial closed after 24 months because of low recruitment. Power analysis estimated 1130 women
needed to rule out an increase in adverse perinatal outcome, with at most 5%
Dates of the study: June 2011 to June 2013
Funding sources: Erasmus Medical Center
Declarations of interest: none mentioned
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Unclear risk No details on method for sequence generation in abstract presented at poster
session
Allocation concealment
(selection bias)
Unclear risk No details on method of allocation concealment in abstract presented at
poster session
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details on blinding in abstract presented at poster session
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details on blinding in abstract presented at poster session
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk States that analysis was by intention-to-treat and numbers randomised ap-
peared to be accounted for in analyses
Selective reporting (re-
porting bias)
Unclear risk Difficult to tell, because some of the outcomes reported in the trial registry
record and protocol were not reported in the abstract, but probably due to the
trial stopping early, and so many of the outcomes may not have been report-
ed, rather than selectively reported.
Other bias Unclear risk The trials was stopped early because of low recruitment.
Duvekot 2015  (Continued)
 
 
Methods Randomisation was generated from a random number sequence table. Blind allocation was made us-
ing consecutively sealed envelopes. Odd numbers = aggressive management, even numbers = expec-
tant management. Analysis was by ITT. Follow-up was judged to be 100%.
Participants 30 pregnant women with severe PE between 28 and 33 + 6 days gestation. Severe PE was defined as a
BP > 180/120 mmHg on 2 occasions, 30 minutes apart; or a BP between 160 to 180/110 to 120 mmHg
on 2 occasions, 6 hrs apart. All participants had > 500 mg of proteinuria on a 24 hr urine collection mea-
sure. Exclusions were women who needed delivery for either a maternal or fetal condition in the 1st 24
hrs.
Interventions The group assigned to aggressive management were given steroids, and then allowed 48 hrs to lapse
before either an induction of labour was attempted or CS carried out. Women assigned to expectant
management also had steroids, but were then managed conservatively with bedrest, observations, and
nifedipine to control their BP. The indications for delivery in expectant management were: imminent
eclampsia, deteriorating renal function, spontaneous preterm labour, absent EDF, or a non-reassuring
CTG, and reaching 34 weeks.
Outcomes Women: days of hospitalisation, imminent eclampsia, eclampsia, HELLP, CS, imminent eclampsia and
deteriorating renal function
Baby: days gained in utero, gestation at delivery, birthweight, admission to SCBU, SGA, stillbirth,
neonatal death, 5-minute Apgar score
Notes In table 2, the total number in the expectant arm was recorded as 10 participants, however, the detail
of the table and percentages use the denominator 15. The total looked as if it was a typographical er-
ror. We are seeking information from the author.
Dates of the study: January 2001 and May 2002
Mesbah 2003 
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Funding sources: none disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “Random sequence generated by going through random number tables till we
obtained 30 pairs of numbers from 01 to 30.”
Allocation concealment
(selection bias)
Low risk “Randomly assigned to one of two management groups by withdrawing the
next envelope in a series of 30 consecutively numbered, sealed, opaque en-
velopes.”
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No blinding reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No blinding reported
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 41 women were recruited, but 11 (27%) judged too compromised for expectant
management, and were delivered by CS
5 patients from the expectant group appeared to be missing from results table
2 – no explanation
Selective reporting (re-
porting bias)
Low risk All expected outcomes appear to be reported
Other bias High risk Severe group were excluded from the study, and no baseline characteristics
described for this group of patients. 5 patients missing from results for expec-
tant group and no explanation given in the text
Mesbah 2003  (Continued)
 
 
Methods Described as 'randomised'. No further information. Blinding in the assessment of outcome not men-
tioned. Analysis - ITT basis. Follow-up - 100%
Participants 38 women with severe PE at 28 to 34 weeks' gestation. Severe PE defined in 4 ways, depending on BP,
proteinuria, and symptoms. Women were either already admitted for bedrest and later met criteria, or
admitted because of severe PE, and after 48 hrs stabilisation met entry criteria. 10 primigravidae per
group
Exclusions: oral antihypertensives before trial entry. Fetal or maternal complications necessitating de-
livery within 48 hrs (20 women excluded before randomisation for this reason)
Interventions All eligible women in 48 hrs before trial entry: MgSO4 for 24 hrs. If BP 160/110 mmHg, or more, 6.25 mg
dihydralazine boluses. If steroids not already given, betamethasone 12 mg IM, and again after 24 hrs
Interventionist: delivery by either CS or by induction of labour, depending on obstetric circumstances.
If cervix not favourable, prostaglandin E2 tablets. If still not favourable after 24 hrs, CS
Expectant: bedrest on high-risk obstetric ward, BP controlled with prazosin, weekly betamethasone.
Maternal and fetal condition monitored intensively. Delivery at 34 weeks, unless indicated earlier
Odendaal 1990 
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Outcomes Women: CS, abruption
Baby: stillbirth, neonatal death, HMD, NEC, pneumothorax, ventilation, days in NICU (mean), birth-
weight (mean), gestation at delivery (mean)
Notes 8 women in the interventionist group and 5 in the expectant group deteriorated while in hospital on
bedrest and were randomised immediately.
Dates of the study: the trial recruited from January 1986 to January 1988
Funding sources: South African Medical Research Council
Declarations of interest: none stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not described
Allocation concealment
(selection bias)
Unclear risk Not described
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 58 women eligible with severe PE; 20 had to be delivered before randomisa-
tion because of severe maternal complications or fetal distress  
20 were randomised to the aggressive-management group; 18 were ran-
domised to the expectant group – not clear from results tables how many
analysed – but presume no loss to follow-up as not described in the text
ITT not stated
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported                                                                            
Other bias Low risk Groups seemed similar – including 20 women excluded prior to randomisation
(correspondence with author)
Odendaal 1990  (Continued)
 
 
Methods Randomisation was by computer-generated random number. Concealment of allocation by consecu-
tively-numbered sealed, opaque, envelopes. Analysis - ITT basis. Follow-up - 100%
Participants 95 women with severe PE at 28 to 32 weeks' gestation. Severe PE defined as a persistent elevation of BP
≥ 160/110 mmHg, proteinuria > 500 mg in 24 hrs, and uric acid > 5 mg/dL.
Exclusions: associated medical conditions, renal failure, diabetes or connective tissue disorders, asso-
ciated obstetric complications, multiple pregnancies, preterm labour, fetal compromise (estimated fe-
tal weight < 5th percentile), platelet count < 100,000/mm3
Sibai 1994 
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Interventions All eligible women in 24 hrs before trial entry: betamethasone 12 mg, repeated after 24 hrs, MgSO4 for
24 hrs. If BP 160/110 mmHg or more, hydralazine or nifedipine, depending on clinician preference
Interventionist: delivery by either CS or by induction of labour, on the basis of their obstetric condition
Expectant: maternal and fetal monitoring on an antenatal ward. If either the maternal or fetal condi-
tion deteriorated, or they reached 34 weeks' gestation, delivery using the most appropriate method
Outcomes Women: eclampsia, gestation at delivery (mean), CS, placental abruption, HELLP syndrome, renal fail-
ure, pulmonary oedema, postpartum length of stay
Baby: birthweight (mean), admission to NICU, length of stay in NICU, SGA, RDS, NEC, bronchopul-
monary dysplasia, cerebral haemorrhage
Notes Dates of the study: the trial recruited from January 1991 to July 1993
Funding sources: not stated
Declarations of interest: none declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “Computer-generated random assignments”
Allocation concealment
(selection bias)
Low risk “Consecutively numbered, sealed, opaque envelopes”
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 129 women had severe PE, but 32 of these were ineligible because they met 1
or more of the exclusion criteria, and 2 refused to participate – 95 women were
randomised (expectant management N = 49; aggressive management N = 46)
All women appeared to have been accounted for in the results. Appeared to be
ITT                        
Selective reporting (re-
porting bias)
Low risk All expected outcomes appeared to have been reported upon
Other bias Low risk The 2 groups were similar with respect to clinical and laboratory findings.
Sibai 1994  (Continued)
 
 
Methods Multi-centre randomised controlled trial
Setting: 69 hospitals in 13 European countries
Participants 547 women (588 babies) recruited, outcomes were available on 547 mothers (587 babies)
Thornton 2004 (GRIT) 
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Inclusion criteria: pregnant women with fetal compromise between 24 and 36 weeks, an umbilical
artery Doppler waveform recorded, and clinical uncertainty whether immediate delivery was indicated
Interventions Immediate delivery (N = 273; IPD N = 141): deliver now, within 48 hrs to permit completion of a steroid
course
Delayed delivery (N = 274; IPD N = 121): defer delivery, meaning until delivery could safely be delayed
no longer
Outcomes Infant survival to hospital discharge and the Griffith's development quotient at 2 years of age
The trial was for compromised preterm fetus: a subset of women within this trial had severe PE.  IPD
were available for this subset and these were the data which were extracted and analysed for this re-
view. The outcomes for this subset were as follows.
For the woman: CS
For the baby:
• intraventricular haemorrhage, hypoxic ischaemic encephalopathy, or both• Apgar score at 5 minutes• neonatal seizures• NEC• ventilation• measures of long-term growth and development (e.g. CP diagnosis, Griffiths score)• gestational age at birth
Notes Only a subset of IPD data were included and analysed in this review (women with hypertension plus ei-
ther proteinuria or IUGR).
Dates of the study: November 1993 to March 2001
Funding sources: UK Medical Research Council, European Union Concerted Action, and the Dutch
Princess Beatrix Foundation
Declarations of interest: none mentioned
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “A paper-based number sequence with balanced blocks of 8 to 12 weeks used
except during office hours, when a computer-generated sequence was used”
Allocation concealment
(selection bias)
Low risk “An independent programmer organised allocation, using both randomisation
and minimisation.” “The process was designed to mask allocation from partic-
ipating clinicians, including those with access to the central trial office.”
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Not possible to blind – but most of the outcomes not likely to be influenced by
lack of blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Some blinding of outcome assessment for long-term outcomes, such as Grif-
fiths assessment: “Assessors were masked to the child’s group allocations.”
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk A subset of IPD data was provided of women with severe PE (N = 262 – hyper-
tension, IUGR, proteinuria, or a combination). It was not possible to tell how
Thornton 2004 (GRIT)  (Continued)
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complete this dataset was, as it was provided by the authors of the original
study.
Selective reporting (re-
porting bias)
Low risk All expected outcomes appeared to have been reported upon.
Other bias Unclear risk Unclear.  Other bias may have been introduced, as only a subset of the original
randomised sample provided data for analysis.
Thornton 2004 (GRIT)  (Continued)
 
 
Methods Randomised controlled trial (open label). 8 tertiary teaching hospitals in Latin America with experience
of managing severe PE. 425 eligible women, 158 declined to participate, 267 randomised
Participants Inclusion criteria: pregnant women between 28 and 33 weeks' gestation with severe PE, severe gesta-
tional hypertension, and super-imposed PE
Exclusion criteria: pregnant women with HELLP syndrome, renal failure, vaginal bleeding, spontaneous
rupture of membranes, placenta praevia, gestational diabetes or diabetes mellitus, autoimmune dis-
ease, fetal growth restriction, reduced amniotic fluid, and reversed EDF
Interventions Experimental intervention: delivery between 24 and 72 hrs following the administration of glucocorti-
coids for fetal lung maturity. Total number randomised: N = 133
Control or comparison intervention: glucocorticoid administration, then planned expectant manage-
ment with delivery for maternal or fetal indications, or reaching 34 weeks. Total number randomised: N
= 134 (131 analysed)
Outcomes Primary outcome: perinatal mortality (fetal and neonatal death)
Secondary outcomes: composite neonatal morbidities (RDS, IVH, necrotizing enterocolitis, neonatal
sepsis); neonatal data (birthweight, SGA, Apgar scores at 1 and 5 minutes, NICU admission, length of
NICU admission stay, sex (female) of baby); caesarean delivery, pregnancy prolongation, maternal mor-
bidities (placental abruption, pulmonary edema, the HELLP syndrome, renal insufficiency, eclampsia,
disseminated intravascular coagulation, oliguria), and death
Notes Dates of the study: August 2010 to August 2012
Funding sources: Marjorie Milham Research Fund, Pennsylvania Hospital, Perelman School of Medicine,
University of Pennsylvannia
Declarations of interest: "The authors report no conflict of interest."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly allocated, using computer-generated code with variable block size
of 4 and 6
Allocation concealment
(selection bias)
Unclear risk Central allocation for each hospital made by the principal investigator. Sealed
envelopes were used, though does not specify whether they were sequentially
numbered and opaque
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Open-label trial due to the nature of the intervention
Vigil-De Gracia 2013 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk An attempt was made to blind the treatment allocation to the data abstracter
- especially the neonatologist. However, most outcomes depended on clinical
diagnoses and others on the responses to those diagnoses.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The authors stated that 2 patients did not complete the study because they
refused to remain in the hospital, and 1 did not receive the correct treatment
due to physician error. These 3 patients were excluded from the analysis. They
said the data were not available for these 3 women. All 3 women were in the
expectant management group. The authors reported that the analysis was on
an ITT basis.
Selective reporting (re-
porting bias)
Unclear risk The trial was registered. However, the planned secondary outcomes were list-
ed only as "perinatal complications and maternal complications".
Other bias Unclear risk Baseline characteristics - no differences between groups. Minimal loss to fol-
low-up. Two women refused to remain in hospital and one women received in-
correct treatment due to physician error.
Vigil-De Gracia 2013  (Continued)
BP: blood pressure
CP: cerebral palsy
CS: caesarean section
CTG: cardiotocography
EDF: end diastolic flow
HELLP: haemolysis, elevated liver enzymes, and lowered platelets
HMD: hyaline membrane disease
hrs: hours
IM: intramuscular
IPD: individual patient data
ITT: intention-to-treat
IUGR: intrauterine growth restriction
MgSO4: magnesium sulphate
NEC: necrotising enterocolitis
NICU: neonatal intensive care unit
PE: pre-eclampsia
RDS: respiratory distress syndrome
SCBU: special care baby unit
SGA: small-for-gestational age
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Gruppo di Studio1998 Not women with severe pre-eclampsia
This randomised trial compared routine treatment with calcium channel blockers in mild to mod-
erate hypertension.
Langenveld 2011 Not women with severe pre-eclampsia
This multi-centre, randomised trial compared induction of labour versus expectant monitoring for
gestation hypertension or mild pre-eclampsia.
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Comparison 1.   Interventionist care versus expectant (delayed delivery) care for severe pre-eclampsia
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Maternal death 2 320 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Eclampsia 2 359 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.06, 15.58]
3 Pulmonary oedema 3 415 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.07, 3.00]
4 HELLP syndrome 2 359 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.62, 1.91]
5 Death of the baby (all still-
births, neonatal, and infant
deaths)
6 760 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.74, 1.60]
6 Death of the baby (sub-
grouped by time of death)
6   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Stillbirth 5 700 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.07, 1.23]
6.2 Perinatal death 3 343 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.62, 1.99]
6.3 Neonatal death 5 485 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.80, 2.19]
6.4 Death after 28 days 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.18, 18.21]
7 Intraventricular haemor-
rhage or hypoxic ischaemic
encephalopathy
2 537 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [1.15, 3.29]
8 Caesarean section 6 745 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.12]
9 Renal failure 3 397 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.05, 1.99]
10 Placental abruption 4 453 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.18, 0.96]
11 Hyaline membrane dis-
ease
2 133 Risk Ratio (M-H, Fixed, 95% CI) 2.30 [1.39, 3.81]
12 Baby ventilated 2 300 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [1.11, 2.02]
13 Gestation at birth (days) 4 425 Mean Difference (IV, Random, 95% CI) -9.91 [-16.37, -3.45]
14 Necrotising enterocolitis 4 670 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.84, 3.81]
15 Small-for-gestational age 3 400 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.24, 0.61]
16 Low Apgar score at five
minutes (< 7 at five minutes)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.87, 2.50]
17 Neonatal seizures 1 262 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.27, 24.43]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
18 Measures of long-term
growth & development (cere-
bral palsy)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 6.01 [0.75, 48.14]
19 Measures of long-term
growth & development (poor
hearing, use of hearing aid)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.07, 1.74]
20 Measures of long-term
growth & development (im-
paired vision)
1 262 Risk Ratio (M-H, Fixed, 95% CI) 4.29 [0.51, 36.22]
21 Admission to neonatal in-
tensive care unit
3 400 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.89, 1.60]
22 Length of stay in neonatal
intensive care unit (days)
3 400 Mean Difference (IV, Random, 95% CI) 7.38 [-0.45, 15.20]
 
 
Analysis 1.1.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 1 Maternal death.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Duvekot 2015 0/26 0/30   Not estimable
Vigil-De Gracia 2013 0/133 0/131   Not estimable
   
Total (95% CI) 159 161 Not estimable
Total events: 0 (Interventionist), 0 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours intervention 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.2.   Comparison 1 Interventionist care versus expectant
(delayed delivery) care for severe pre-eclampsia, Outcome 2 Eclampsia.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sibai 1994 0/46 0/49   Not estimable
Vigil-De Gracia 2013 1/133 1/131 100% 0.98[0.06,15.58]
   
Total (95% CI) 179 180 100% 0.98[0.06,15.58]
Total events: 1 (Interventionist), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
Favours intervention 5000.002 100.1 1 Favours expectant
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Analysis 1.3.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 3 Pulmonary oedema.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Duvekot 2015 0/26 1/30 40.93% 0.38[0.02,9.01]
Sibai 1994 0/46 0/49   Not estimable
Vigil-De Gracia 2013 1/133 2/131 59.07% 0.49[0.05,5.37]
   
Total (95% CI) 205 210 100% 0.45[0.07,3]
Total events: 1 (Interventionist), 3 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=0.83(P=0.41)  
Favours intervention 100.1 50.2 20.5 1 Favours expectant
 
 
Analysis 1.4.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 4 HELLP syndrome.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sibai 1994 1/46 2/49 9.65% 0.53[0.05,5.68]
Vigil-De Gracia 2013 21/133 18/131 90.35% 1.15[0.64,2.06]
   
Total (95% CI) 179 180 100% 1.09[0.62,1.91]
Total events: 22 (Interventionist), 20 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.38, df=1(P=0.54); I2=0%  
Test for overall effect: Z=0.3(P=0.76)  
Favours intervention 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.5.   Comparison 1 Interventionist care versus expectant (delayed delivery) care for
severe pre-eclampsia, Outcome 5 Death of the baby (all stillbirths, neonatal, and infant deaths).
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sibai 1994 0/46 0/49   Not estimable
Duvekot 2015 1/29 1/31 2.32% 1.07[0.07,16.31]
Odendaal 1990 5/20 3/18 7.59% 1.5[0.42,5.41]
Mesbah 2003 6/15 4/15 9.61% 1.5[0.53,4.26]
Vigil-De Gracia 2013 13/137 12/138 28.74% 1.09[0.52,2.31]
Thornton 2004 (GRIT) 22/141 20/121 51.74% 0.94[0.54,1.64]
   
Total (95% CI) 388 372 100% 1.08[0.74,1.6]
Total events: 47 (Interventionist), 40 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.86, df=4(P=0.93); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
Favours intervention 100.1 50.2 20.5 1 Favours expectant
 
 
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
30
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 1.6.   Comparison 1 Interventionist care versus expectant (delayed delivery) care
for severe pre-eclampsia, Outcome 6 Death of the baby (subgrouped by time of death).
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.6.1 Stillbirth  
Sibai 1994 0/46 0/49   Not estimable
Mesbah 2003 0/15 0/15   Not estimable
Vigil-De Gracia 2013 1/137 1/138 12.53% 1.01[0.06,15.94]
Odendaal 1990 0/20 1/18 19.8% 0.3[0.01,6.97]
Thornton 2004 (GRIT) 1/141 5/121 67.67% 0.17[0.02,1.45]
Subtotal (95% CI) 359 341 100% 0.3[0.07,1.23]
Total events: 2 (Interventionist), 7 (Expectant)  
Heterogeneity: Tau2=0; Chi2=1, df=2(P=0.61); I2=0%  
Test for overall effect: Z=1.67(P=0.09)  
   
1.6.2 Perinatal death  
Odendaal 1990 1/20 2/18 11.66% 0.45[0.04,4.55]
Mesbah 2003 6/15 4/15 22.15% 1.5[0.53,4.26]
Vigil-De Gracia 2013 13/137 12/138 66.2% 1.09[0.52,2.31]
Subtotal (95% CI) 172 171 100% 1.11[0.62,1.99]
Total events: 20 (Interventionist), 18 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.91, df=2(P=0.64); I2=0%  
Test for overall effect: Z=0.34(P=0.73)  
   
1.6.3 Neonatal death  
Sibai 1994 0/46 0/49   Not estimable
Duvekot 2015 1/29 1/31 4.36% 1.07[0.07,16.31]
Odendaal 1990 3/20 1/18 4.75% 2.7[0.31,23.69]
Mesbah 2003 6/15 4/15 18.05% 1.5[0.53,4.26]
Thornton 2004 (GRIT) 21/141 15/121 72.84% 1.2[0.65,2.23]
Subtotal (95% CI) 251 234 100% 1.32[0.8,2.19]
Total events: 31 (Interventionist), 21 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.59, df=3(P=0.9); I2=0%  
Test for overall effect: Z=1.08(P=0.28)  
   
1.6.4 Death after 28 days  
Odendaal 1990 2/20 1/18 100% 1.8[0.18,18.21]
Subtotal (95% CI) 20 18 100% 1.8[0.18,18.21]
Total events: 2 (Interventionist), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.5(P=0.62)  
Test for subgroup differences: Chi2=3.92, df=1 (P=0.27), I2=23.44%  
Favours intervention 100.1 50.2 20.5 1 Favours expectant
 
 
Analysis 1.7.   Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe
pre-eclampsia, Outcome 7 Intraventricular haemorrhage or hypoxic ischaemic encephalopathy.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thornton 2004 (GRIT) 34/141 16/121 94.53% 1.82[1.06,3.14]
Vigil-De Gracia 2013 4/137 1/138 5.47% 4.03[0.46,35.59]
Favours intervention 100.1 50.2 20.5 1 Favours expectant
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Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 278 259 100% 1.94[1.15,3.29]
Total events: 38 (Interventionist), 17 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.48, df=1(P=0.49); I2=0%  
Test for overall effect: Z=2.48(P=0.01)  
Favours intervention 100.1 50.2 20.5 1 Favours expectant
 
 
Analysis 1.8.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 8 Caesarean section.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Mesbah 2003 11/15 9/15 3.79% 1.22[0.73,2.04]
Odendaal 1990 14/20 15/18 7.14% 0.84[0.59,1.2]
Duvekot 2015 21/26 27/30 13.78% 0.9[0.72,1.12]
Sibai 1994 39/46 36/49 14.89% 1.15[0.94,1.42]
Vigil-De Gracia 2013 118/133 124/131 30.04% 0.94[0.87,1.01]
Thornton 2004 (GRIT) 137/141 107/121 30.35% 1.1[1.02,1.18]
   
Total (95% CI) 381 364 100% 1.01[0.91,1.12]
Total events: 340 (Interventionist), 318 (Expectant)  
Heterogeneity: Tau2=0.01; Chi2=13.69, df=5(P=0.02); I2=63.49%  
Test for overall effect: Z=0.2(P=0.84)  
Favours intervention 20.5 1.50.7 1 Favours expectant
 
 
Analysis 1.9.   Comparison 1 Interventionist care versus expectant
(delayed delivery) care for severe pre-eclampsia, Outcome 9 Renal failure.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Odendaal 1990 0/20 1/18 34.26% 0.3[0.01,6.97]
Sibai 1994 0/46 0/49   Not estimable
Vigil-De Gracia 2013 1/133 3/131 65.74% 0.33[0.03,3.12]
   
Total (95% CI) 199 198 100% 0.32[0.05,1.99]
Total events: 1 (Interventionist), 4 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=1.22(P=0.22)  
Favours intervention 1000.01 100.1 1 Favours expectant
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Analysis 1.10.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 10 Placental abruption.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Duvekot 2015 0/26 1/30 7.93% 0.38[0.02,9.01]
Sibai 1994 2/46 2/49 10.99% 1.07[0.16,7.25]
Odendaal 1990 3/20 4/18 23.9% 0.68[0.17,2.62]
Vigil-De Gracia 2013 2/133 10/131 57.18% 0.2[0.04,0.88]
   
Total (95% CI) 225 228 100% 0.42[0.18,0.96]
Total events: 7 (Interventionist), 17 (Expectant)  
Heterogeneity: Tau2=0; Chi2=2.35, df=3(P=0.5); I2=0%  
Test for overall effect: Z=2.05(P=0.04)  
Favours intervention 100.1 50.2 20.5 1 Favours expectant
 
 
Analysis 1.11.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 11 Hyaline membrane disease.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Odendaal 1990 11/20 4/18 28.33% 2.48[0.96,6.41]
Sibai 1994 23/46 11/49 71.67% 2.23[1.23,4.04]
   
Total (95% CI) 66 67 100% 2.3[1.39,3.81]
Total events: 34 (Interventionist), 15 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.85); I2=0%  
Test for overall effect: Z=3.23(P=0)  
Favours intervention 100.1 50.2 20.5 1 Favours expectant
 
 
Analysis 1.12.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 12 Baby ventilated.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Odendaal 1990 7/20 2/18 4.66% 3.15[0.75,13.25]
Thornton 2004 (GRIT) 66/141 40/121 95.34% 1.42[1.04,1.93]
   
Total (95% CI) 161 139 100% 1.5[1.11,2.02]
Total events: 73 (Interventionist), 42 (Expectant)  
Heterogeneity: Tau2=0; Chi2=1.15, df=1(P=0.28); I2=13.4%  
Test for overall effect: Z=2.62(P=0.01)  
Favours intervention 20.5 1.50.7 1 Favours expectant
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Analysis 1.13.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 13 Gestation at birth (days).
Study or subgroup Interventionist Expectant Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Odendaal 1990 20 211 (15) 18 223 (13) 20.74% -12[-20.9,-3.1]
Mesbah 2003 15 213 (12) 15 217 (11) 21.99% -4[-12.24,4.24]
Sibai 1994 46 216 (14) 49 233 (11) 28.24% -17[-22.08,-11.92]
Thornton 2004 (GRIT) 141 217 (17) 121 223 (21) 29.02% -6[-10.68,-1.32]
   
Total *** 222   203   100% -9.91[-16.37,-3.45]
Heterogeneity: Tau2=31.74; Chi2=12.3, df=3(P=0.01); I2=75.61%  
Test for overall effect: Z=3.01(P=0)  
Favours expectant 2010-20 -10 0 Favours intervention
 
 
Analysis 1.14.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 14 Necrotising enterocolitis.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Sibai 1994 5/46 0/49 4.85% 11.7[0.67,205.88]
Odendaal 1990 3/20 1/18 10.54% 2.7[0.31,23.69]
Vigil-De Gracia 2013 1/137 2/138 19.95% 0.5[0.05,5.49]
Thornton 2004 (GRIT) 9/141 6/121 64.66% 1.29[0.47,3.51]
   
Total (95% CI) 344 326 100% 1.79[0.84,3.81]
Total events: 18 (Interventionist), 9 (Expectant)  
Heterogeneity: Tau2=0; Chi2=3.28, df=3(P=0.35); I2=8.43%  
Test for overall effect: Z=1.5(P=0.13)  
Favours intervention 2000.005 100.1 1 Favours expectant
 
 
Analysis 1.15.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 15 Small-for-gestational age.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mesbah 2003 2/15 9/15 16.85% 0.22[0.06,0.86]
Sibai 1994 5/46 15/49 27.19% 0.36[0.14,0.9]
Vigil-De Gracia 2013 13/137 30/138 55.96% 0.44[0.24,0.8]
   
Total (95% CI) 198 202 100% 0.38[0.24,0.61]
Total events: 20 (Interventionist), 54 (Expectant)  
Heterogeneity: Tau2=0; Chi2=0.82, df=2(P=0.66); I2=0%  
Test for overall effect: Z=4.03(P<0.0001)  
Favours intervention 100.1 50.2 20.5 1 Favours expectant
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Analysis 1.16.   Comparison 1 Interventionist care versus expectant (delayed delivery) care
for severe pre-eclampsia, Outcome 16 Low Apgar score at five minutes (< 7 at five minutes).
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thornton 2004 (GRIT) 31/141 18/121 100% 1.48[0.87,2.5]
   
Total (95% CI) 141 121 100% 1.48[0.87,2.5]
Total events: 31 (Interventionist), 18 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.45(P=0.15)  
Favours intervention 200.05 50.2 1 Favours delay
 
 
Analysis 1.17.   Comparison 1 Interventionist care versus expectant (delayed
delivery) care for severe pre-eclampsia, Outcome 17 Neonatal seizures.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thornton 2004 (GRIT) 3/141 1/121 100% 2.57[0.27,24.43]
   
Total (95% CI) 141 121 100% 2.57[0.27,24.43]
Total events: 3 (Interventionist), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.82(P=0.41)  
Favours intervention 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.18.   Comparison 1 Interventionist care versus expectant (delayed delivery) care for
severe pre-eclampsia, Outcome 18 Measures of long-term growth & development (cerebral palsy).
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thornton 2004 (GRIT) 7/141 1/121 100% 6.01[0.75,48.14]
   
Total (95% CI) 141 121 100% 6.01[0.75,48.14]
Total events: 7 (Interventionist), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.69(P=0.09)  
Favours intervention 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.19.   Comparison 1 Interventionist care versus expectant (delayed delivery) care for severe pre-
eclampsia, Outcome 19 Measures of long-term growth & development (poor hearing, use of hearing aid).
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thornton 2004 (GRIT) 2/141 5/121 100% 0.34[0.07,1.74]
   
Total (95% CI) 141 121 100% 0.34[0.07,1.74]
Favours intervention 1000.01 100.1 1 Favours expectant
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Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 2 (Interventionist), 5 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.29(P=0.2)  
Favours intervention 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.20.   Comparison 1 Interventionist care versus expectant (delayed delivery) care for
severe pre-eclampsia, Outcome 20 Measures of long-term growth & development (impaired vision).
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Thornton 2004 (GRIT) 5/141 1/121 100% 4.29[0.51,36.22]
   
Total (95% CI) 141 121 100% 4.29[0.51,36.22]
Total events: 5 (Interventionist), 1 (Expectant)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.34(P=0.18)  
Favours intervention 1000.01 100.1 1 Favours expectant
 
 
Analysis 1.21.   Comparison 1 Interventionist care versus expectant (delayed delivery)
care for severe pre-eclampsia, Outcome 21 Admission to neonatal intensive care unit.
Study or subgroup Interventionist Expectant Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Mesbah 2003 15/15 10/15 25.2% 1.48[1.02,2.13]
Sibai 1994 46/46 37/49 37.05% 1.32[1.12,1.55]
Vigil-De Gracia 2013 95/137 102/138 37.75% 0.94[0.81,1.09]
   
Total (95% CI) 198 202 100% 1.19[0.89,1.6]
Total events: 156 (Interventionist), 149 (Expectant)  
Heterogeneity: Tau2=0.05; Chi2=12.34, df=2(P=0); I2=83.79%  
Test for overall effect: Z=1.19(P=0.23)  
Favours intervention 20.5 1.50.7 1 Favours expectant
 
 
Analysis 1.22.   Comparison 1 Interventionist care versus expectant (delayed delivery) care
for severe pre-eclampsia, Outcome 22 Length of stay in neonatal intensive care unit (days).
Study or subgroup Interventionist Expectant Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Sibai 1994 46 36.6 (17.4) 49 20.2 (14) 30.14% 16.4[10.02,22.78]
Mesbah 2003 15 22.3 (5.8) 15 15.7 (4.5) 34.73% 6.6[2.89,10.31]
Vigil-De Gracia 2013 137 13.8 (14) 138 13.4 (15) 35.14% 0.4[-3.03,3.83]
   
Total *** 198   202   100% 7.38[-0.45,15.2]
Heterogeneity: Tau2=42.29; Chi2=19.91, df=2(P<0.0001); I2=89.95%  
Favours intervention 2010-20 -10 0 Favours expectant
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Study or subgroup Interventionist Expectant Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=1.85(P=0.06)  
Favours intervention 2010-20 -10 0 Favours expectant
 
 
A P P E N D I C E S
Appendix 1. Search methods for ICTRP and ClinicalTrials.gov
ICTRP
preeclampsia AND remote AND term
preeclampsia AND expectant
preeclampsia AND "before term"
ClinicalTrials.gov
Advanced search
Study type: Interventional
Condition: preeclampsia
Other terms: preterm or expectant
W H A T ' S   N E W
 
Date Event Description
27 November 2017 New search has been performed Search updated and two new trials included. The review now in-
cludes six trials with 748 women. A 'Summary of findings' table
was added for this update.
27 November 2017 New citation required but conclusions
have not changed
The overall conclusions have not changed substantially. In this
update, there was no evidence of a clear difference between
groups for caesarean section, length of stay in the neonatal in-
tensive care unit, or admission to neonatal intensive care unit.
 
H I S T O R Y
Protocol first published: Issue 2, 2001
Review first published: Issue 3, 2002
 
Date Event Description
10 July 2013 New citation required and conclusions
have changed
Expectant management may be associated with decreased mor-
bidity for the baby.
28 February 2013 New search has been performed Search updated. Methods updated.
Three studies identified from updated search (Duvekot 2011a;
Thornton 2004 (GRIT); Langenveld 2011). One study has been in-
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Date Event Description
cluded (Thornton 2004 (GRIT)); one is an ongoing study (Duvekot
2011a); and one study has been excluded (Langenveld 2011).
One study previously in studies awaiting assessment in the last
update has now been included (Mesbah 2003).
16 February 2010 New search has been performed Review updated with new report added to Characteristics of
studies awaiting classification.
1 December 2009 Amended Search updated. One new report added to Studies awaiting clas-
sification (Mesbah 2003a).
15 May 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
DC assessed the new trial for risk of bias, extracted the data, and up-dated the text of the review. MM and HA assessed the new trials for
risk of bias, independently extracted the data, and reviewed the final version of the review. LD assessed the new trials for risk of bias and
reviewed the final version. JGT and KW reviewed the final version of the review.
D E C L A R A T I O N S   O F   I N T E R E S T
David Churchill: None
Lelia Duley: LD has been awarded an NIHR research grant for a programme of work on care at very preterm birth.
Jim G Thornton: Jim Thornton is an author on one of the included studies (Thornton 2004 (GRIT)). However, he was not involved in any
assessment, data extraction, or data analysis of this trial.
Mahmoud Moussa: None
Hind SM Ali: None
Kate F Walker: None
S O U R C E S   O F   S U P P O R T
Internal sources• No sources of support supplied
External sources• National Institute for Health Research, UK.
2013 update - UK NIHR Programme of centrally-managed pregnancy and childbirth systematic reviews of priority to the NHS and users
of the NHS: 10/4001/02• UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction-HRP,
Switzerland.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In 2013, we updated the methods. We modified the inclusion criteria to define more clearly the criteria for types of participants:
Women with severe pre-eclampsia up to and including 34 weeks' gestation. Severe pre-eclampsia was defined as:
• high blood pressure, > 140/90 mmHg on two consecutive occasions four or more hours apart, and proteinuria higher than 300 mg/24
hours, or• severe hypertension (blood pressure at least 160 mmHg systolic, or 110 mmHg diastolic) alone; or• hypertension as defined above plus one or more of the following criteria:
Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
38
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• severe proteinuria (usually at least 3 g (range 2 g to 5 g) protein in 24 hours, or 3+ on dipstick);• reduced urinary volume (less than 500 mL in 24 hours), upper abdominal pain, pulmonary oedema;• neurological disturbances (such as headache, visual disturbances, and exaggerated tendon reflexes);• impaired liver function tests, high serum creatinine, low platelets;• suspected intrauterine growth restriction or reduced amniotic fluid.
This latter set of criteria reflect the natural history of the disease and clinical practice when diagnosing severe pre-eclampsia.
We defined primary and secondary outcomes.
We incorporated a 'Summary of findings' table into the 2017 update.
In 2017, we added an additional search of ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP).
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Delivery, Obstetric  [adverse eKects]  [methods];  *Watchful Waiting;  Cerebral Hemorrhage  [epidemiology];  Cesarean Section
 [statistics & numerical data];  Eclampsia  [epidemiology];  Enterocolitis, Necrotizing  [etiology];  HELLP Syndrome  [epidemiology]; 
Hyaline Membrane Disease  [etiology];  Perinatal Mortality;  Pre-Eclampsia  [*therapy];  Pulmonary Edema  [epidemiology];  Randomized
Controlled Trials as Topic
MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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